A U.S. appeals panel on Wednesday denied a patent challenge against Biogen’s multiple sclerosis drug Tecfidera, putting off the early launch of a generic version by Mylan and sending shares of Biogen surging.

Mylan, the generic drug maker, had filed an inter partes review seeking to overturn the last remaining patent on Tecfidera, Biogen’s most important multiple sclerosis drug. That patent was not set to expire until 2028.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I have just learned that Tecfidera is dimethyl fumarate. That is, an off patent cheap chemical that can be bought from chemical suppliers at a whopping 100$ for 100g, good for about 200 daily doses. Or, less than 200$/year instead of 60K/year.
    Once again, a pathetically “innovative” drug and an FDA validated scam

Your daily dose of news in health and medicine

Privacy Policy